newsfilter
← Latest News
GlobeNewswire·

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

NTLA
  • Intellia Therapeutics expects to complete lonvo-z commercial readiness efforts before the March 10, 2027 PDUFA target date.
  • The company will present new lonvo-z patient perspectives & Phase 1/2 durability data at an investor webcast & multiple presentations at ACAAI 2026.
  • Enrollment in the MAGNITUDE-2 Phase 3 trial for ATTRv-PN is complete, while MAGNITUDE enrollment for ATTR-CM has advanced.
  • Existing cash resources & a recent term loan facility are expected to fund operations through 2028 & beyond lonvo-z's anticipated commercial launch.
  • The FDA accepted the BLA for lonvo-z with Priority Review, establishing a PDUFA date of March 10, 2027, without an advisory committee meeting.
  • lonvo-z is a one-time in vivo CRISPR therapy intended to permanently lower kallikrein & bradykinin levels to eliminate HAE attacks.
  • The company completed field organization deployment & deepened payer engagement to prepare for a Q1 2027 U.S. launch of lonvo-z.
  • Nex-z, a one-time in vivo CRISPR therapy for ATTR amyloidosis, aims to halt & reverse disease by reducing TTR protein levels.
  • Intellia entered a non-dilutive $400 million senior secured term loan facility with OrbiMed to support financial flexibility.
  • Jing L. Marantz, M.D., Ph.D., was appointed Executive Vice President & Chief Medical Officer to lead drug development & regulatory functions.
  • Intellia will participate in upcoming events including the American Heart Association Scientific Sessions, ACAAI 2026, & the Jefferies London Healthcare Conference.
  • Cash, cash equivalents, & marketable securities totaled $614.8 million as of September 30, 2026.
  • Collaboration revenue was $7.2 million for the third quarter of 2026, down from $13.8 million in the same period last year.
  • R&D expenses were $83.3 million for the quarter, reduced by lower external costs & stock-based compensation, partially offset by higher headcount costs.
  • G&A expenses increased to $46.1 million due to commercial infrastructure buildout, legal, facility, & compensation costs.
  • The company reported a net loss of $127.5 million for the third quarter of 2026, including an unrealized investment loss of $10.4 million.